Inflammatory Bowel Disease–associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria

Abstract Adherent-invasive Escherichia coli have been suggested to play a pivotal role within the pathophysiology of inflammatory bowel disease (IBD). Autoantibodies against distinct splicing variants of glycoprotein 2 (GP2), an intestinal receptor of the bacterial adhesin FimH, frequently occur in...

Full description

Saved in:
Bibliographic Details
Published inInflammatory bowel diseases Vol. 26; no. 12; pp. 1856 - 1868
Main Authors Derer, Stefanie, Brethack, Ann-Kathrin, Pietsch, Carlotta, Jendrek, Sebastian T, Nitzsche, Thomas, Bokemeyer, Arne, Hov, Johannes R, Schäffler, Holger, Bettenworth, Dominik, Grassl, Guntram A, Sina, Christian
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.12.2020
Lippincott-Raven Publishers
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Adherent-invasive Escherichia coli have been suggested to play a pivotal role within the pathophysiology of inflammatory bowel disease (IBD). Autoantibodies against distinct splicing variants of glycoprotein 2 (GP2), an intestinal receptor of the bacterial adhesin FimH, frequently occur in IBD patients. Hence, we aimed to functionally characterize GP2-directed autoantibodies as a putative part of IBD’s pathophysiology. Ex vivo, GP2-splicing variant 4 (GP2#4) but not variant 2 was expressed on intestinal M or L cells with elevated expression patterns in IBD patients. The GP2#4 expression was induced in vitro by tumor necrosis factor (TNF)-α. The IBD-associated GP2 autoantibodies inhibited FimH binding to GP2#4 and were decreased in anti-TNFα-treated Crohn’s disease patients with ileocolonic disease manifestation. In vivo, mice immunized against GP2 before infection with adherent-invasive bacteria displayed exacerbated intestinal inflammation. In summary, autoimmunity against intestinal expressed GP2#4 results in enhanced attachment of flagellated bacteria to the intestinal epithelium and thereby may drive IBD’s pathophysiology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izaa069